JP Patent

JP6275242B2 — 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８−メチル）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法

Assigned to オゲダ エス．エー． · Expires 2018-02-07 · 8y expired

What this patent protects

Patent listed against Veozah.

Drugs covered by this patent

Patent Metadata

Patent number
JP6275242B2
Jurisdiction
JP
Classification
—
Expires
2018-02-07
Drug substance claim
No
Drug product claim
No
Assignee
オゲダ エス．エー．
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.